What Are Senolytics? Clearing Senescent Cells Explained

What Are Senescent Cells?

Every cell in your body has a limited capacity to divide. When a cell reaches the end of its division capacity, accumulates too much DNA damage, experiences severe oxidative stress, or receives a strong oncogenic signal, it faces a choice: it can die (apoptosis) or enter senescence. A senescent cell is one that chooses the latter: it permanently stops dividing but refuses to die.

In the short term, this is adaptive. Senescent cells play important roles in wound healing, embryonic development, and tumour suppression. A cell on the edge of cancerous transformation is much safer as a non-dividing senescent cell than as a proliferating tumour cell. The problem emerges over decades: as we age, the rate at which cells become senescent exceeds the rate at which the immune system clears them, and senescent cells accumulate throughout the body's tissues.

The result is a growing population of cells that biologists sometimes call "zombie cells" because they are neither properly alive (contributing to tissue function) nor dead (cleared by normal cellular housekeeping). They persist in a metabolically active, damage-spreading state, releasing a constant stream of signals that corrupt the cellular environment around them.

Senescent cells are identified in the laboratory by several markers: elevated p16 protein (a cell-cycle brake protein), the presence of gamma-H2AX (a DNA damage marker), increased senescence-associated beta-galactosidase activity, and the distinctive secretory output that defines the SASP. As these markers accumulate in tissues, they signal that senescent cell burden is rising, which correlates directly with the physical signs of aging.

The SASP: Why Senescent Cells Drive Aging

The most damaging aspect of senescent cells is not their failure to function, but their active secretion of harmful molecules through the Senescence-Associated Secretory Phenotype. SASP is the mechanism through which a relatively small number of senescent cells can cause disproportionately large damage throughout the surrounding tissue.

SASP secretions fall into several categories. Pro-inflammatory cytokines, primarily interleukin-6 (IL-6) and interleukin-8 (IL-8), create a local and systemic inflammatory environment. These cytokines are the same ones elevated in many age-related diseases including type 2 diabetes, cardiovascular disease, neurodegeneration, and osteoarthritis. Matrix metalloproteinases (MMPs) degrade the structural proteins of the extracellular matrix, weakening tissue integrity and disrupting the scaffolding that supports healthy cell function. Growth factors distort local signalling, promoting abnormal cell behaviour in the senescent cell's neighbourhood. Perhaps most insidiously, SASP factors can trigger the senescence of neighbouring healthy cells in a process called "bystander senescence," creating a propagating wave of dysfunction.

The term "inflammaging" describes the chronic low-grade inflammatory state that SASP contributes to across decades of accumulation. This inflammaging is now recognised as a major driver of age-related disease burden, operating across virtually every organ system. The heart, brain, liver, kidneys, joints, skin, and vasculature are all affected by the systemic effects of SASP from senescent cells distributed throughout the body.

SASP also directly undermines NAD+ metabolism. Senescent cells express high levels of CD38, an NADase enzyme that degrades NAD+ to generate calcium-signalling messengers. As senescent cell burden increases with age, CD38 activity increases systemically, accelerating the NAD+ decline that also occurs through declining NAMPT activity. This is one of the mechanisms through which the three aging pillars, NAD+ decline, oxidative stress, and cellular senescence, actively interact and amplify each other.

The Evidence That Senescent Cells Drive Aging: A Landmark Study

The Baker 2016 paper shifted the field from correlation to causation. Prior research had established that senescent cells accumulate with age and are present at sites of age-related disease. Baker's work demonstrated that removing those cells in normally aging animals produces lifespan extension comparable to some of the most dramatic genetic longevity interventions ever reported. This established senescent cell clearance as a valid, causal anti-aging intervention strategy, providing the scientific foundation for the entire senolytic field.

How Senolytics Work: Targeting Senescent Cell Survival

Senolytics work by exploiting a fundamental vulnerability of senescent cells: they have upregulated specific anti-apoptotic survival pathways to resist the cell death signals that their own SASP and DNA damage status would normally trigger. This is one reason they are so difficult for the body to clear naturally once they accumulate in large numbers. The same survival machinery that keeps them alive is also what makes them targetable.

Several molecular pathways keep senescent cells alive against their own pro-apoptotic signals. The BCL-2 family of anti-apoptotic proteins (BCL-2, BCL-XL, BCL-W) is upregulated in many types of senescent cells. The PI3K/AKT survival signalling pathway is hyperactive. HSP90 and related chaperone pathways are engaged. The p21 pathway provides a second-line growth arrest mechanism that backs up p16-mediated arrest.

Senolytic compounds disrupt one or more of these survival pathways, selectively tipping the balance in senescent cells toward apoptosis. Normal cells, which do not rely on these survival mechanisms as heavily, are largely unaffected at senolytic doses. This selectivity is the key property that distinguishes senolytics from broad cytotoxic compounds, which would kill both senescent and healthy cells indiscriminately.

Different senolytic compounds target different survival mechanisms, which is why combination approaches have been explored: covering multiple survival pathways increases the breadth of senescent cell types that can be cleared. The most studied pharmaceutical combination uses Dasatinib (a BCL-2 pathway inhibitor) and Quercetin (a PI3K/BCL-2 multi-pathway inhibitor), but Quercetin and Berberine are the accessible dietary senolytics with the most evidence for broad use.

Quercetin: The Dietary Senolytic with a NAD+ Bonus

Quercetin is a flavonoid found in onions, capers, apples, and tea. As a dietary compound, its concentrations in food are too low to achieve senolytic effects, but as a supplement it reaches concentrations relevant to its multiple anti-aging mechanisms.

Quercetin's senolytic activity was first characterised by Zhu, Tchkonia, Pirtskhalava, and colleagues at the Mayo Clinic in 2015, which established it as one of the original compounds to receive the "senolytic" classification. The mechanism involves inhibition of PI3K signalling, which reduces AKT-dependent survival signalling in senescent cells, and modulation of BCL-2 family anti-apoptotic proteins, reducing the survival advantage that senescent cells have erected. By disrupting these pathways, Quercetin pushes senescent cells past their apoptotic threshold, triggering selective self-destruction while leaving normal cells unaffected at the doses used.

Quercetin also inhibits CD38, the NADase enzyme that senescent cells express at high levels and that degrades NAD+. This dual mechanism makes Quercetin uniquely positioned in the aging biology framework: it acts as a senolytic (clearing senescent cells) while simultaneously protecting NAD+ from CD38-mediated destruction. This connects the Senolytics pillar directly to the NAD+ pillar, with Quercetin sitting at their intersection.

AMPK activation is a third mechanism through which Quercetin supports healthy aging. AMPK (AMP-activated protein kinase) is the cellular energy sensor that signals nutritional stress, activates autophagy (cellular cleaning), and slows the accumulation of senescent cells by promoting cellular stress responses that prevent the initial senescence trigger. Quercetin's AMPK activation is consistent with the broader metabolic effects seen with caloric restriction mimetics.

Berberine: AMPK Activation and the Senescence Accumulation Brake

Berberine is an isoquinoline alkaloid found in several plants including Berberis vulgaris and Coptis chinensis. It has a long history of use in traditional medicine for metabolic conditions, and modern research has established its mechanism of action primarily through AMPK activation.

AMPK activation by Berberine serves several anti-senescence functions. Activated AMPK promotes autophagy, the cellular self-digestion process that clears damaged organelles and protein aggregates before they trigger senescence signals. By keeping cellular housekeeping systems active, Berberine slows the rate at which cells accumulate sufficient damage to enter senescence in the first place. This makes Berberine primarily a senescence accumulation inhibitor rather than a direct senolytic, though some evidence suggests it can also promote apoptosis in senescent cells at higher concentrations.

Berberine also modulates the mTOR pathway. mTOR (mechanistic target of rapamycin) is a master cellular growth sensor that, when chronically active, suppresses autophagy and accelerates cellular senescence. AMPK and mTOR are in a reciprocal relationship: AMPK activation suppresses mTOR. Berberine's AMPK activation therefore indirectly reduces mTOR-mediated autophagy suppression, maintaining the cellular cleaning systems that prevent senescence accumulation.

Metabolic regulation is a secondary but important benefit of Berberine. Its AMPK activation improves insulin sensitivity, regulates blood glucose, and reduces lipid accumulation, all of which are relevant to the metabolic dysfunction that both drives and results from cellular senescence. Metabolic stress is itself a trigger for cellular senescence, so reducing metabolic dysfunction reduces one input into the senescence accumulation cycle.

Senolytics in the Solensis Three-Pillar Framework

Solensis is built around a three-pillar model of biological aging that no other supplement brand has assembled as a coherent system: NAD+ decline and Sirtuin dysfunction (addressed by NMN and Resveratrol), oxidative stress and DNA damage (addressed by L-Glutathione and CoQ10), and cellular senescence (addressed by Quercetin and Berberine). Senolytics represent the third pillar that most longevity supplement brands have never addressed.

The three pillars do not operate in isolation. Senescent cells, through their SASP, generate reactive oxygen species that feed into the oxidative stress pillar. Through CD38 overexpression, they accelerate NAD+ decline that the NMN pillar addresses. Through SASP-driven chronic inflammation, they impair the Sirtuin activity that Resveratrol supports. Addressing all three pillars simultaneously with a complete longevity stack is mechanistically more coherent than addressing one in isolation.

Quercetin in particular creates a bridge between the Senolytics and NAD+ pillars via CD38 inhibition. When Quercetin clears senescent cells, it reduces one of the primary sources of CD38-mediated NAD+ destruction. When taken alongside NMN and Resveratrol, Quercetin effectively reduces the rate at which newly synthesised NAD+ is degraded by the same inflammatory machinery that NMN is working to counteract. This synergy is one of the scientific reasons the Solensis Longevity Stack makes sense as a system rather than a collection of independent supplements.

Frequently Asked Questions

What are senolytics?

Senolytics are compounds that selectively eliminate senescent cells: permanently arrested, dysfunctional "zombie cells" that accumulate with age and continuously secrete pro-inflammatory molecules (SASP) that damage surrounding tissue. They work by disrupting specific survival pathways that senescent cells rely on, triggering their selective apoptosis while leaving normal cells unaffected.

What are senescent cells, exactly?

Senescent cells are cells that have entered a permanent state of cell-cycle arrest, triggered by DNA damage, telomere shortening, oxidative stress, or oncogene activation. They do not die or self-destruct; instead they remain metabolically active, secreting a damaging mix of pro-inflammatory cytokines, matrix metalloproteinases, and growth factors (SASP) that damage neighbours and promote further senescence in surrounding healthy cells.

How do senescent cells cause aging?

Senescent cells drive aging through SASP, which creates chronic inflammation ("inflammaging"), degrades extracellular matrix, impairs stem cell function, and triggers bystander senescence in neighbouring cells. They also overexpress CD38, which degrades NAD+, accelerating the cellular energy decline that compounds with age. Research has established that this accumulation causally drives organ deterioration and shortened lifespan, not merely correlates with it.

Is quercetin a senolytic?

Yes. Quercetin was identified as one of the first dietary senolytics by Mayo Clinic researchers. It induces selective apoptosis in senescent cells via PI3K and BCL-2 family pathway inhibition. It also inhibits CD38 to protect NAD+, and activates AMPK to slow new senescent cell accumulation. This triple mechanism makes it the most multi-functional dietary senolytic compound currently available.

What is SASP?

SASP (Senescence-Associated Secretory Phenotype) is the distinctive mix of pro-inflammatory cytokines (IL-6, IL-8), matrix metalloproteinases, and growth factors that senescent cells continuously secrete. SASP creates the chronic inflammation that drives age-related disease across virtually every organ system. It also degrades the extracellular matrix and can trigger bystander senescence in neighbouring healthy cells.

Do senolytics actually work in humans?

The most compelling evidence comes from animal studies, where senescent cell clearance extended healthy lifespan by 20-30% and improved multi-organ function. Human trials are ongoing and early stage. For accessible dietary senolytics like Quercetin, evidence includes animal studies, in vitro selective senescent cell clearance data, and well-characterised mechanistic pathways. The field is advancing rapidly and Quercetin and Berberine represent the most evidence-supported accessible options currently available.

How do senolytics fit with NMN and NAD+ supplementation?

Senolytics and NAD+ supplementation address complementary aging pathways. NMN restores NAD+ to support cellular energy and Sirtuin activity. Senolytics clear the senescent cells whose SASP actively drives chronic inflammation and whose CD38 overexpression destroys NAD+. Quercetin uniquely bridges both by clearing senescent cells AND inhibiting CD38. Together they form two of the three pillars of the Solensis longevity framework.